Status:
COMPLETED
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Asthma
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Brief Summary
A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.
Detailed Description
A prospective, open-label, non-interventional, multicentre study in adult patients with asthma or COPD who are treated with Salmeterol/fluticasone Easyhaler. During the study the Salmeterol/fluticason...
Eligibility Criteria
Inclusion
- Main
- Male or female patients with asthma or COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the study
- Age ≥18 years.
- Written informed consent obtained.
- Main
Exclusion
- Pregnant or lactating female patients.
- Participation in other clinical studies during the study.
- Known hypersensitivity (allergy) to salmeterol, fluticasone propionate or the excipient lactose
- Any significant medical disease or condition or other factor that might interfere with study assessments or study participation.
Key Trial Info
Start Date :
January 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 13 2020
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT03755544
Start Date
January 16 2019
End Date
February 13 2020
Last Update
February 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lungenpraxis
Hamburg, Germany